Dr. Chandler Park discusses the importance of genetic testing and personalized care in patients with genitourinary cancers.

Adding a personalized mRNA vaccine to standard treatment could offer new hope for pancreatic cancer patients, a small yet ...

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a ...

The annual BioTech Breakthrough Awards program evaluates top companies, solutions, and products in the global life sciences and biotechnology markets. This year's program attracted thousands of ...

Predicting how cancer patients will respond to treatment remains a critical challenge. Immune checkpoint inhibitors (ICIs), a ...

On August 15, Tevogen Bio entered into a definitive agreement for a $6 million Series C Preferred Stock investment (“Series C”). The shares of the Series C have a 7.5% annual dividend and are ...

Chinese Society of Clinical Oncology Breast Cancer (CSCO BC) guidelines mark a significant milestone in breast cancer treatment, seamlessly integrating cutting-edge international research with Chinese ...

Tevogen Bio is a clinical-stage specialty immunotherapy company harnessing one of nature ... Tevogen Bio’s leadership believes that accessible personalized therapeutics are the next frontier of ...

An innovative machine learning model predicts the success of immune checkpoint inhibitors in cancer patients using routine blood tests and clinical data, outperforming traditional methods like tumor ...

A study at Mount Sinai has shown that children with a high tolerance for peanuts can significantly increase their resistance ...

A groundbreaking study has uncovered how specific genetic mutations influence cancer treatment outcomes -- insights that could help doctors tailor treatments more effectively. The largest study of its ...

The leading nonprofit Colorectal Cancer Alliance (Alliance) is making bold strides in its mission to put an end to the ...